Литература
1. McWilliams M.M., Chennathukuzhi V.M. Recent advances in uterine fibroid etiology // Semin. Reprod. Med. 2017. Vol. 35, N 2. P. 181-189. doi: 10.1055/s-0037-1599090.
2. Terrence D.L. A comprehensive review of the pharmacologic management of uterine leiomyoma // Biomed. Res. Int. 2018. Vol. 2018. Article ID 2414609. Published online 2018 Jan 28. doi: 10.1155/2018/ 2414609.
3. Stewart E.A., Cookson C.L., Gandolfo R.A., Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review // Br. J. Obstet. Gynaecol. (BJOG: An International Journal of Obstetrics and Gynaecology). 2017. Vol. 124. P. 1501-1512.
4. Parazzini F., Tozzi L., Bianchi S. Pregnancy outcome and uterine fibroids // Best Pract. Res. Clin. Obstet. Gynaecol. 2016. Vol. 34. P. 74-84. doi: 10.1016/j.bpobgyn.2015.11.017.
5. Psathas G., Zarokosta M., Zoulamoglou M., Chrysikos D. et al. Leiomyomatosis peritonealis disseminata: a case report and meticulous review of the literature // Int. J. Surg. Case Rep. 2018. Vol. 40. P. 105-108.
6. Nappi L., Sorrentino F., Angioni S., Pontis A. et al. Leiomyomatosis peritonealis disseminata (LPD) ten years after laparoscopic myomectomy associated with ascites and lymph nodes enlargement: a case report // Int. J. Surg. Case Rep. 2018. Vol. 25. P. 1-3.
7. Wright J.D., Herzog T.J., Tsui J. et al. Nationwide trends in the performance of inpatient hysterectomy in the United States // Obstet. Gynecol. 2013. Vol. 122, N 2, pt 1. P. 233-241. doi: 10.1097/aog.0b013e31 8299a6cf.
8. Wu J.M., Wechter M.E., Geller E.J., Nguyen T.V. et al. Hysterectomy rates in the United States // Obstet. Gynecol. 2017. Vol. 110, N 5. P. 10911095. doi: 10.1097/01.AOG.0000285997.38553.4b.
9. Carlson K.J., Nichols D.H., Schiff I. Indications for hysterectomy // N. Engl. J. Med. 1993. Vol. 328, N 12. P. 856-860. doi: 10.1056/ NEJM199303253281207.
10. Cardozo E.R., Clark A.D., Banks N.K., Henne M.B. et al. The estimated annual cost of uterine leiomyomata in the United States // Am. J. Obstet. Gynecol. 2012. Vol. 206, N 3. P. 211.e9. doi: 10.1016/j.ajog.2011.12.002.
11. Soliman A.M., Yang H., Du E.X., Kelkar S.S. et al. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013 // Am. J. Obstet. Gynecol. 2015. Vol. 213, N 2. P. 141-160. doi: 10.1016/j.ajog.2015.03.019.
12. Patel A., Malik M., Britten J., Cox J. et al. Alternative therapies in management of leiomyomas // Fertil. Steril. 2014. Vol. 102, N 3. P. 649655. doi: 10.1016/j.fertnstert.2014.07.008.
13. Тихомиров А.Л., Залеева Е.В. Применение левоноргестрел-рилизинг-системы в комплексном лечении миомы матки // Гинекология. 2005. № 1. С. 63-65.
14. Merrill R.M. Hysterectomy surveillance in the United States, 1997 through 2005 // Med. Sci. Monit. 2008. Vol. 14, N 1. P. 24-31.
15. Committee on Practice B-G. Practice bulletin No. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction // Obstet. Gynecol. 2013. Vol. 122, N 1. P. 176-185. doi: 10.1097/01. AOG.0000431815.52679.bb.
16. Lethaby A., Duckitt K., Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding // Cochrane Database Syst. Rev. (Online). 2013. Vol. 1. CD000400.
17. Ylikorkala O., Pekonen F.R. Naproxen reduces idiopathic but not fibro-myoma-induced menorrhagia // Obstet. Gynecol. 1986. Vol. 68, N 1. P. 10-12.
18. Клинические рекомендации "Миома матки: диагностика, лечение и реабилитация" : письмо Министерства здравоохранения РФ от 2.10.2015 г. № 15-4/10/2-5805.
19. Lukes A.S., Kouides P.A., Moore K.A. Tranexamic acid: A novel oral formulation for the treatment of heavy menstrual bleeding // Womens Health J. (WHJ). 2011. Vol. 7, N 2. P. 151-158. doi: 10.2217/whe.11.9. doi: 10.2217/WHE.11.9.
20. Wellington K., Wagstaff A. J. Tranexamic acid: a review of its use in the management of menorrhagia // Drugs. 2003. Vol. 63, N 13. P. 14171433. doi: 10.2165/00003495-200363130-00008.
21. Marjoribanks J., Lethaby A., Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding // Cochrane Database Syst. Rev. 2016. Vol. 1. CD003855.
22. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas // Obstet. Gynecol. 2008. Vol. 112, N 2. Pt 1. P. 387-400. doi: 10.1097/AOG.0b013e318183fbab.
23. Qin J., Yang T., Kong F., Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies // Arch. Gynecol. Obstet. 2013. Vol. 288, N 1. P. 139-148. doi: 10.1007/s00404-013-2797-9.
24. Радзинский В.Е., Тотчиев Г.Ф. Миома матки: курс на органосохранение : информационный бюллетень. М. : Редакция журнала StatusPraesens, 2014. 24 с.
25. Harrison-Woolrych M., Robinson R. Fibroid growth in response to high-dose progestogen // Fertil. Steril. 1995. Vol. 64, N 1. P. 191-192.
26. Venkatachalam S., Bagratee J. S., Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study // J. Obstet. Gynaecol. 2004. Vol. 24, N 7. P. 798-800. doi: 10.1080/01443610400009543.
27. Mercorio F., De Simone R., Di Spiezio Sardo A. et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia // Contraception. 2003. Vol. 67, N 4. P. 277-280. doi: 10.1016/S0010-7824(02)00522-X.
28. Wrona W. The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids // Prz. Menopauzalny. 2017. Vol. 16, N 4. P. 129-132. doi: 10.5114/pm.2017.72758.
29. Bulun S.E., Economos K., Miller D., Simpson E.R. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors // J. Clin. Endocrinol. Metab. 1994. Vol. 79, N 6. P. 1831-1834. doi: 10.1210/jcem.79.6.7989490.
30. Iveson T.J., Smith I.E., Ahern J., Smithers D.A. et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women // J. Clin. Endocrinol. Metab. 1993. Vol. 77, N 2. P. 324-331. doi: 10.1210/jcem.77.2.8345035.
31. Parsanezhad M.E., Azmoon M., Alborzi S. et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letro-zole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status // Fertil. Steril. 2010. Vol. 93, N 1. P. 192-198. doi: 10.1016/j.fertnstert.2008.09.064.
32. Attilakos G., Fox R. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole // J. Obstet. Gynaecol. 2005. Vol. 25, N 6. P. 609-610. doi: 10.1080/01443610500242465.
33. Varelas F.K., Papanicolaou A.N., Vavatsi-Christaki N., Makedos G.A. et al. The effect of anastrazole on symptomatic uterine leiomyomata // Obstet. Gynecol. 2007. Vol. 110, N 3. P. 643-649. doi: 10.1097/01. aog.0000279151.20878.60.
34. Shozu M., Murakami K., Segawa T., Kasai T. et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor // Fertil. Steril. 2003. Vol. 79, N 3. P. 628-631. doi: 10.1016/S0015-0282(02)04761-1.
35. Hilario S.G., Bozzini N., Borsari R., Baracat E.C. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients // Fertil. Steril. 2009. Vol. 91, N 1. P. 240-243. doi: 10.1016/j.fertn-stert.2007.11.006.
36. Song H., Lu D., Navaratnam K., Shi G. Aromatase inhibitors for uterine fibroids // Cochrane Database Syst. Rev. 2013. Vol. 10. CD009505.
37. Olive D.L., Lindheim S.R., Pritts E.A. Non-surgical management of leiomyoma: impact on fertility // Curr. Opin. Obstet. Gynecol. 2014. Vol. 16, N 3. P. 239-243. doi: 10.1097/00001703-200406000-00006.
38. Patel A. Formulation of 99mTechnetium-labeled leuprolide loaded liposomes and its biodistribution study in New Zealand white female rabbits for assessment of its uterine targeting efficiency // Drug Deliv. Transl. Res. 2018. Vol. 8, N 1. P. 43-53. doi: 10.1007/s13346-017-0432-1.
39. Malik M., Britten J., Cox J., Patel A. et al. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones // Fertil. Steril. 2016. Vol. 105, N 1. P. 214-224. doi: 10.1016/j.fertnstert.2015.09.006.
40. Archer D.F. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study // Fertil. Steril. 2017. Vol. 108, N 1. P. 152-160.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1.
41. Gonzalez-Barcena D., Alvarez R.B., Ochoa E.P. et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix // Hum. Reprod. 1997. Vol. 12, N 9. P. 2028-2035. doi: 10.1093/humrep/12.9.2028.
42. Felberbaum R.E., Germer U., Ludwig M. et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix // Hum. Reprod. 1998. Vol. 13, N 6. P. 16601668. doi: 10.1093/humrep/13.6.1660.
43. Felberbaum R.E., Kupker W., Krapp M., Gehl B. et al. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide) // Reprod. Biomed. Online. 2013. Vol. 3, N 1. P. 14-18. doi: 10.1016/S1472-6483(10)61957-8.
44. Flierman P.A., Oberye J.J.L., Van Der Hulst V.P.M., De Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix // Br. J. Obstet. Gynaecol. (BJOG: An International Journal of Obstetrics and Gynaecology). 2005. Vol. 112, N 5. P. 638-642. doi: 10.1111/j.1471-0528.2004.00504.x.
45. Liu C. Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial // Medicine (Baltimore). 2017. Vol. 96, N 7. Article ID e6124. doi: 10.1097/ MD.0000000000006124.
46. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J. et al. Immu-nohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy // Hum. Reprod. 1999. Vol. 14, N 11. P. 2844-2850. doi: 10.1093/humrep/14.11.2844.
47. Fiscella K., Eisinger S.H., Meldrum S., Feng C. et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial // Obstet. Gynecol. 2006. Vol. 108, N 6. P. 1381-1387. doi: 10.1097/01.AOG.0000243776.23391.7b.
48. Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S. et al. Twelvemonth safety and efficacy of low-dose mifepristone for uterine myomas // J. Minim. Invasive Gynecol. 2005. Vol. 12, N 3. P. 227-233. doi: 10.1016/ j.jmig.2005.01.022.
49. Steinauer J., Pritts E.A., Jackson R., Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata // Obstet. Gynecol. 2004. Vol. 103, N 6. P. 1331-1336. doi: 10.1097/01.AOG.0000127622.63269.8b.
50. Tristan M., Orozco L.J., Steed A., Ramirez-Morera A. et al. Mifepristone for uterine fibroids // Cochrane Database Syst. Rev. (Online). 2012. Vol. 8. CD007687.
51. Bouchard P., Chabbert-Buffet N., Fauser B.C.J.M. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety // Fertil. Steril. 2011. Vol. 96, N 5. P. 1175-1189. doi: 10.1016/j.fertnstert.2011.08.021.
52. Kulshrestha V., Kriplani L., Agarwal N. et al. Low dose Mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India // Indian J. Med. Res. 2013. Vol. 137. P. 1154-1162.
53. Carbonell J.L., Acosta R., Perez Y. et al. Safety of 10 mg versus 5 mg of Mifepristone during 9 months for the treatment of uterine fibroids. Double-blind randomized clinical trial // Int. J. Womens Health. 2013. Vol. 5. P. 115-124. doi: 10.2147/IJWH.S33125.
54. Kapur A. Efficacy of use of long-term, low-dose Mifepristone for the treatment of fibroids // J. Obstet. Gynaecol. India. 2016. Vol. 66, suppl. 1. P. 494-498. doi: 10.1007/s13224-016-0861-7.
55. Donnez J., Vazquez F., Tomaszewski J. et al. Long-term treatment of uterine fibroids with ulipristal acetate // Fertil. Steril. 2014. Vol. 101, N 6. P. 1565.e18. doi: 10.1016/j.fertnstert.2014.02.008.
56. De Milliano I., Van Hattum D., Ket J.C.F., Huirne J.A.F. et al. Endometrial changes during ulipristal acetate use: a systematic review // Eur. J. Obstet. Gynecol. Reprod. Biol. 2017. Vol. 214. P. 56-64. doi: 10.1016/j.ejogrb.2017.04.042.
57. Donnez J., Dolmans M.-M. Uterine fibroid management: From the present to the future // Hum. Reprod. Update. 2016. Vol. 22, N 6. P. 665686. doi: 10.1093/humupd/dmw023.
58. Women Taking Esmya for Uterine Fibroids to Have Regular Liver Tests While EMA Review is Ongoing. Eur. Med. Agency, 2018.
59. PRAC. Women Taking Esmya for Uterine Fibroids to have Regular Liver Tests While EMA Review is Ongoing. Eur. Med. Agency. 2018. Vol. 44. P. 2017-2019. http://www.ema.europa.eu/ema/index.jsp7curUpages/medicines/human/referrals/Esmya/human_referral_prac_000070.jsp&mid=
WC0b01ac05805c516f . (date of access April 8, 2018)
60. О новых данных по безопасности лекарственного препарата Эсмия®. Информационное письмо от 10.04.2018 № 01И-902/18.
References
1. McWilliams M.M., Chennathukuzhi V.M. Recent advances in uterine fibroid etiology. Semin Reprod Med. 2017; 35 (2): 181-9. doi: 10.1055/s-0037-1599090.
2. Terrence D.L. A comprehensive review of the pharmacologic management of uterine leiomyoma. Biomed Res Int. 2018; 2018: 2414609. Published online 2018 Jan 28. doi: 10.1155/2018/2414609.
3. Stewart E.A., Cookson C.L., Gandolfo R.A., Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. Br J Obstet Gynaecol (BJOG: An International Journal of Obstetrics and Gynaecology). 2017; 124: 1501-12.
4. Parazzini F., Tozzi L., Bianchi S. Pregnancy outcome and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016; 34: 74-84. doi: 10.1016/j.bpobgyn.2015.11.017.
5. Psathas G., Zarokosta M., Zoulamoglou M., Chrysikos D., et al. Leiomyomatosis peritonealis disseminata: a case report and meticulous review of the literature. Int J Surg Case Rep. 2018; 40: 105-8.
6. Nappi L., Sorrentino F., Angioni S., Pontis A., et al. Leiomyomatosis peritonealis disseminata (LPD) ten years after laparoscopic myomectomy associated with ascites and lymph nodes enlargement: a case report. Int J Surg Case Rep. 2018; 25: 1-3.
7. Wright J.D., Herzog T.J., Tsui J., et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol. 2013; 122 (2, pt 1): 233-41. doi: 10.1097/aog.0b013e318299a6cf.
8. Wu J.M., Wechter M.E., Geller E.J., Nguyen T.V., et al. Hysterectomy rates in the United States. Obstet Gynecol. 2017; 110 (5): 1091-5. doi: 10.1097/01.AOG.0000285997.38553.4b.
9. Carlson K.J., Nichols D.H., Schiff I. Indications for hysterectomy. N Engl J Med. 1993; 328 (12): 856-60. doi: 10.1056/NEJM199303253281207.
10. Cardozo E.R., Clark A.D., Banks N.K., Henne M.B., et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012; 206 (3): 211.e9. doi: 10.1016/j.ajog.2011.12.002.
11. Soliman A.M., Yang H., Du E.X., Kelkar S.S., et al. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. Am J Obstet Gynecol. 2015; 213 (2): 141-60. doi: 10.1016/j.ajog.2015.03.019.
12. Patel A., Malik M., Britten J., Cox J., et al. Alternative therapies in management of leiomyomas. Fertil Steril. 2014; 102 (3): 649-55. doi: 10.1016/j.fertnstert.2014.07.008.
13. Tikhomirov AL, Zaleyeva EV The use of levonorgestrel-releasing system in the complex treatment of uterine myomas. Ginekologiya [Gynecology]. 2005; (1): 63-5.
14. Merrill R.M. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit. 2008; 14 (1): 24-31.
15. Committee on Practice B-G. Practice bulletin No. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013; 122 (1): 176-85. doi: 10.1097/01. AOG.0000431815.52679.bb.
16. Lethaby A., Duckitt K., Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev (Online). 2013; 1: CD000400.
17. Ylikorkala O., Pekonen F.R. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol. 1986; 68 (1): 10-2.
18. Clinical recommendations "Uterine fibroids: diagnosis, treatment and rehabilitation": letter of the Ministry of Health of the Russian Federation No. 15-4 /10/2-5805 dated October 2, 2015. (in Russian)
19. Lukes A.S., Kouides P.A., Moore K.A. Tranexamic acid: A novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health J (WHJ). 2011; 7 (2): 151-8. doi: 10.2217/whe.11.9. doi: 10.2217/ WHE.11.9.
20. Wellington K., Wagstaff A. J. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003; 63 (13): 1417-33. doi: 10.2165/00003495-200363130-00008.
21. Marjoribanks J., Lethaby A., Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2016; 1: CD003855.
22. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008; 112 (2, pt 1): 387-400. doi: 10.1097/ AOG.0b013e318183fbab.
23. Qin J., Yang T., Kong F., Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013; 288 (1): 139-48. doi: 10.1007/s00404-013-2797-9.
24. Radzinsky V.E., Totchiev G.F. Uterine fibroids: a course in organ preservation: a newsletter. Moscow: Redaktsiya zhurnala "StatusPraesens", 2014. 24 p. (in Russian)
25. Harrison-Woolrych M., Robinson R. Fibroid growth in response to high-dose progestogen. Fertil Steril. 1995; 64 (1): 191-2.
26. Venkatachalam S., Bagratee J. S., Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004; 24 (7): 798-800. doi: 10.1080/01443610400009543.
27. Mercorio F., De Simone R., Di Spiezio Sardo A., et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003; 67 (4): 277-80. doi: 10.1016/S0010-7824(02)00522-X.
28. Wrona W. The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids. Prz Menopauzalny. 2017; 16 (4): 12932. doi: 10.5114/pm.2017.72758.
29. Bulun S.E., Economos K., Miller D., Simpson E.R. CYP19 (aroma-tase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab. 1994; 79 (6): 1831-4. doi: 10.1210/ jcem.79.6.7989490.
30. Iveson T.J., Smith I.E., Ahern J., Smithers D.A., et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab. 1993; 77 (2): 324-31. doi: 10.1210/jcem.77.2.8345035.
31. Parsanezhad M.E., Azmoon M., Alborzi S., et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letro-zole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010; 93 (1): 192-8. doi: 10.1016/j.fertnstert.2008.09.064.
32. Attilakos G., Fox R. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole. J Obstet Gynaecol. 2005; 25 (6): 609-10. doi: 10.1080/01443610500242465.
33. Varelas F.K., Papanicolaou A.N., Vavatsi-Christaki N., Makedos G.A., et al. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007; 110 (3): 643-9. doi: 10.1097/01. aog.0000279151.20878.60.
34. Shozu M., Murakami K., Segawa T., Kasai T., et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril. 2003; 79 (3): 628-31. doi: 10.1016/S0015-0282(02)04761-1.
35. Hilrio S.G., Bozzini N., Borsari R., Baracat E.C. Action of aroma-tase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril. 2009; 91 (1): 240-3. doi: 10.1016/j.fertnstert.2007. 11.006.
36. Song H., Lu D., Navaratnam K., Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013; 10: CD009505.
37. Olive D.L., Lindheim S.R., Pritts E.A. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol. 2014; 16 (3): 239-43. doi: 10.1097/00001703-200406000-00006.
38. Patel A. Formulation of 99mTechnetium-labeled leuprolide loaded liposomes and its biodistribution study in New Zealand white female rabbits for assessment of its uterine targeting efficiency. Drug Deliv Transl Res. 2018; 8 (1): 43-53. doi: 10.1007/s13346-017-0432-1.
39. Malik M., Britten J., Cox J., Patel A., et al. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril. 2016; 105 (1): 214-24. doi: 10.1016/j.fertnstert.2015.09.006.
40. Archer D.F. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017; 108 (1): 152-60.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1.
41. Gonzalez-Barcena D., Alvarez R.B., Ochoa E.P., et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997; 12 (9): 2028-35. doi: 10.1093/humrep/12.9.2028.
42. Felberbaum R.E., Germer U., Ludwig M., et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod. 1998; 13 (6): 1660-8. doi: 10.1093/humrep/13.6.1660.
43. Felberbaum R.E., Kupker W., Krapp M., Gehl B., et al. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online. 2013; 3 (1): 14-8. doi: 10.1016/S1472-6483(10)61957-8.
44. Flierman P.A., Oberye J.J.L., Van Der Hulst V.P.M., De Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. Br J Obstet Gynaecol. (BJOG: An International Journal of Obstetrics and Gynaecology). 2005; 112 (5): 638-42. doi: 10.1111/j.1471-0528.2004.00504.x.
45. Liu C. Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial. Medicine (Baltimore). 2017; 96 (7): e6124. doi: 10.1097/MD.0000000000006124.
46. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., et al. Immu-nohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999; 14 (11): 2844-50. doi: 10.1093/ humrep/14.11.2844.
47. Fiscella K., Eisinger S.H., Meldrum S., Feng C., et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006; 108 (6): 1381-7. doi: 10.1097/01.AOG.0000243776.23391.7b.
48. Eisinger S.H., Bonfiglio T., Fiscella K., Meldrum S., et al. Twelvemonth safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005; 12 (3): 227-33. doi: 10.1016/ j.jmig.2005.01.022.
49. Steinauer J., Pritts E.A., Jackson R., Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004; 103 (6): 1331-6. doi: 10.1097/01.AOG.0000127622. 63269.8b.
50. Tristan M., Orozco L.J., Steed A., Ramirez-Morera A., et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev (Online). 2012; 8: CD007687.
51. Bouchard P., Chabbert-Buffet N., Fauser B.C.J.M. Selective progesterone receptor modulators in reproductive medicine: pharma-oology, clinical, efficacy and safety. Fertil SteriL. 2011; 96 (5): 1175-89. doi: 10.1016/j.fertnstert.2011.08.021.
52. Kulshrestha V., Kriplani L., Agarwal N., et al. Low dose Mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India. Indian J Med Res. 2013; 137: 1154-62.
53. Carbonell J.L., Acosta R., Perez Y., et al. Safety of 10 mg versus 5 mg of Mifepristone during 9 months for the treatment of uterine fibroids. Double-blind randomized clinical trial. Int J Womens Health. 2013; 5: 11524. doi: 10.2147/IJWH.S33125.
54. Kapur A. Efficacy of use of long-term, low-dose Mifepristone for the treatment of fibroids. J Obstet Gynaecol India. 2016; 66 (1): 494-8. doi: 10.1007/s13224-016-0861-7.
55. Donnez J., Vazquez F., Tomaszewski J., et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014; 101 (6): 1565. e18. doi: 10.1016/j.fertnstert.2014.02.008.
56. De Milliano I., Van Hattum D., Ket J.C.F., Huirne J.A.F., et al. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017; 214: 56-64. doi: 10.1016/ j.ejogrb.2017.04.042.
57. Donnez J., Dolmans M.-M. Uterine fibroid management: From the present to the future. Hum Reprod Update. 2016; 22 (6): 665-86. doi: 10.1093/humupd/dmw023.
58. Women Taking Esmya for Uterine Fibroids to Have Regular Liver Tests While EMA Review is Ongoing. Eur. Med. Agency, 2018.
59. PRAC. Women Taking Esmya for Uterine Fibroids to have Regular Liver Tests While EMA Review is Ongoing. Eur. Med. Agency. 2018. Vol. 44. P. 2017-2019. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Esmya/human_referral_prac_000070.jsp&mid=WC0b01ac05805c516f . (date of access April 8, 2018)
60. New data on the safety of Esmia®. The information letter from 10.04.2018 N 01I-902/18. (in Russian)